Annals of Emergency Medicine
Volume 53, Issue 4 , Pages 439-450.e10 , April 2009

Adverse Drug Events Associated With the Antidotes for Methanol and Ethylene Glycol Poisoning: A Comparison of Ethanol and Fomepizole

Presented at the North American Congress of Clinical Toxicology, October 2007, New Orleans, LA.

  • Katherine J. Lepik, BSc(Pharm), MSc

      Affiliations

    • British Columbia Drug and Poison Information Centre, Vancouver, British Columbia, Canada
    • Corresponding Author InformationAddress for correspondence: Katherine J. Lepik, BSc(Pharm), MSc, British Columbia Drug and Poison Information Centre, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6; 604-682-5050, fax 604-806-8262
    • ,
  • Adrian R. Levy, PhD

      Affiliations

    • University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
    • Centre for Health Evaluation and Outcome Sciences at St. Paul's Hospital, Vancouver, British Columbia, Canada
    • ,
  • Boris G. Sobolev, PhD

      Affiliations

    • University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
    • Centre for Clinical Epidemiology and Evaluation at Vancouver General Hospital, Vancouver, British Columbia, Canada
    • ,
  • Roy A. Purssell, MD

      Affiliations

    • British Columbia Drug and Poison Information Centre, Vancouver, British Columbia, Canada
    • Vancouver General Hospital, Department of Emergency Medicine, Vancouver, British Columbia, Canada
    • ,
  • Christopher R. DeWitt, MD

      Affiliations

    • British Columbia Drug and Poison Information Centre, Vancouver, British Columbia, Canada
    • St. Paul's Hospital, Department of Emergency Medicine, Vancouver, British Columbia, Canada
    • ,
  • Gunnar D. Erhardt, MD

      Affiliations

    • British Columbia Drug and Poison Information Centre, Vancouver, British Columbia, Canada
    • Royal Columbian Hospital, Department of Emergency Medicine, New Westminster, British Columbia, Canada
    • ,
  • James R. Kennedy, MD

      Affiliations

    • British Columbia Drug and Poison Information Centre, Vancouver, British Columbia, Canada
    • Department of Internal Medicine, Vancouver, British Columbia, Canada
    • ,
  • Derek E. Daws, BSc(Pharm)

      Affiliations

    • British Columbia Drug and Poison Information Centre, Vancouver, British Columbia, Canada
    • ,
  • Jane L. Brignall, MD

      Affiliations

    • British Columbia Drug and Poison Information Centre, Vancouver, British Columbia, Canada

Received 22 September 2007 ,Revised 28 April 2008 ,Accepted 5 May 2008.

References 

  1. Weiner SW. Toxic alcohols. In:  Flomenbaum NE,  Goldfrank LR,  Hoffman RS, et al. editor. Goldfrank's Toxicologic Emergencies. 8th ed.. New York, NY: McGraw-Hill; 2006;p. 1447–1459
  2. Barceloux DG, Bond GR, Krenzelok EP, et al. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol. 2002;40:415–446
  3. Barceloux DG, Krenzelok EP, Olson K, et al. American Academy of Clinical Toxicology practice guidelines on the treatment of ethylene glycol poisoning. J Toxicol Clin Toxicol. 1999;37:537–560
  4. Bronstein AC, Spyker DA, Cantilena JR, et al. 2006 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol. 2007;45:815–917
  5. Brent J. Antidotes and alcohols: has fomepizole made ethanol an obsolete therapy? Internet J Med Toxicol. Available at: http://www.ijmt.net/ijmt/1_1/1_1_2.html. Accessed June 12, 2008.
  6. Howland MA. Antidotes in depth: fomepizole. In:  Flomenbaum NE,  Goldfrank LR,  Hoffman RS, et al. editor. Goldfrank's Toxicologic Emergencies. 8th ed.. New York, NY: McGraw-Hill; 2006;p. 1460–1464
  7. Mycyk MB, Des Lauriers C, Metz J, et al. Compliance with poison center fomepizole recommendations is suboptimal in cases of toxic alcohol poisoning. Am J Ther. 2006;13:485–489
  8. Green R. The management of severe toxic alcohol ingestion at a tertiary care centre after the introduction of fomepizole. Am J Emerg Med. 2007;25:799–803
  9. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation and reporting. Ann Intern Med. 2004;140:795–801
  10. Gordis L. Chort studies. In: Epidemiology. 2nd ed.. Philadelphia, PA: WB Saunders Co; 2000;p. 131–139
  11. Knaus W, Draper E, Wagner D, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–829
  12. Persson HE, Sjoberg GK, Haines JA, et al. Poisoning Severity Score (Grading of acute poisoning). J Toxicol Clin Toxicol. 1998;36:205–209
  13. WHO-UMC. Definitions: Serious adverse reaction. World Health Organization Collaborating Centre for International Drug Monitoring: Uppsala Monitoring Centre. April 13, 2006. http://www.who-umc.org/DynPage.aspx?id=22680Accessed January 11, 2007
  14. Jazz Pharmaceuticals. Antizol (fomepizole) injection product monograph. http://antizol.info/monograph.htmAccessed March 2, 2007
  15. Kramer MS. Assessing causality of adverse drug reactions: global introspection and its limitations. Drug Inf J. 1986;20:433–437
  16. WHO-UMC. Causality assessment of suspected adverse reactions. World Health Organization Collaborating Centre for International Drug Monitoring: Uppsala Monitoring Centre. http://www.who-umc.org/DynPage.aspx?id=22682Accessed February 16, 2007
  17. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–220
  18. Selvin S. Practical Biostatistical Methods. Belmont, CA: Duxbury Press; 1995;
  19. Peduzzi P, Concato J, Feinstein AR, et al. Importance of events per independent variable in proportional hazards regression analysis II (Accuracy and precision of regression estimates). J Clin Epidemiol. 1995;48:1503–1510
  20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174
  21. Lepik KJ, Brubacher JR, DeWitt CR, et al. Bradycardia and hypotension associated with fomepizole infusion during hemodialysis. Clin Toxicol. 2008;46:570–573
  22. Smithline N, Gardner K. Gaps: anionic and osmolal. JAMA. 1976;236:1594–1597
  23. Macedo AF, Marques FB, Ribeiro CF, et al. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel, according to different levels of imputability. J Clin Pharm Ther. 2003;28:137–143
  24. Roe O. Clinical investigations of methyl alcohol poisoning with special reference to the pathogenesis and treatment of amblyopia. Acta Med Scand. 1943;113:558–608
  25. Seifert SA. Ethanol. In:  Dart RC editors. Medical Toxicology. 3rd ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2004;p. 196–199
  26. Sivilotti ML. Ethanol, isopropanol and methanol. In:  Dart RC editors. Medical Toxicology. 3rd ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2004;p. 1211–1230
  27. Kowalczyk M, Halvorsen S, Ovrebo S, et al. Ethanol treatment in ethylene glycol poisoned patients. Vet Hum Toxicol. 1998;40:225–228
  28. Meyer RJ, Beard ME, Ardagh MW, et al. Methanol poisoning. N Z Med J. 2000;113:11–13
  29. Roy M, Bailey B, Chalut D, et al. What are the adverse effects of ethanol used as an antidote in the treatment of suspected methanol poisoning in children?. J Toxicol Clin Toxicol. 2003;41:155–161
  30. Lister D, Tierney M, Dickinson G. Effectiveness of IV ethanol therapy combined with hemodialysis in the treatment of methanol and ethylene glycol poisoning. Can J Hosp Pharm. 2005;58:142–147
  31. Paasma R, Hovda KE, Tikkerberi A, et al. Methanol mass poisoning in Estonia: outbreak in 154 patients. Clin Toxicol. 2007;45:152–157
  32. Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of ethylene glycol poisoning. N Engl J Med. 1999;340:832–838
  33. Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of methanol poisoning. N Engl J Med. 2001;344:424–429
  34. Jacobsen D, Sebastian CS, Blomstrand R, et al. 4-Methylpyrazole: a controlled study of safety in healthy human subjects after single, ascending doses. Alcohol Clin Exp Res. 1988;12:516–522

 Supervising editor: E. Martin Caravati, MD, MPH

 Author contributions: KJL, ARL, BGS, RAP, and DED conceived and designed the study. KJL and JLB performed data collection. RAP, CRD, GDE, and JRK acted as expert reviewers. BGS was the senior statistician. KJL analyzed the data. KJL drafted the article, and all authors contributed substantially to its revision. KJL takes responsibility for the paper as a whole.

 Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article, that might create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. KJL was supported by a training fellowship from the Michael Smith Foundation for Health Research (MSFHR). ARL is supported by MSFHR Senior Scholar and Canadian Institutes of Health Research New Investigator awards. BGS was supported by the Canada Research Chair Program.

 Publication dates: Available online July 18, 2008.

 Earn CME Credit: Continuing Medical Education is available for this article at: www.ACEP-EMedHome.com.

 Reprints not available from the authors.

PII: S0196-0644(08)00796-8

doi: 10.1016/j.annemergmed.2008.05.008

Annals of Emergency Medicine
Volume 53, Issue 4 , Pages 439-450.e10 , April 2009

Article Tools

* Image Usage & Resolution